Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesClinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor CellsMyeloid derived suppressor cells in chronic myeloid leukemia.The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis.Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma.Myeloid-derived suppressor cells in B cell malignancies.Mechanisms of Immune Tolerance in Leukemia and Lymphoma.A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Myeloid-derived suppressor cells as effectors of immune suppression in cancer.Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.Regulatory myeloid cells: an underexplored continent in B-cell lymphomas.The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.Myeloid-derived suppressor cells coming of age.The Microenvironment in Epstein-Barr Virus-Associated Malignancies.Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies
P2860
Q26748775-AD24FC3F-4D59-4250-8A05-2CF401F06D8AQ28083973-422EDF8B-9671-4E8A-A383-31A50CD00509Q35609094-E1F94FE0-877F-4F37-A413-715EC02A5702Q36174161-166EE407-7A30-46CD-AFFD-8E6C6062AE44Q37317367-5BACEAC8-C569-4FDF-BD59-86B7092F6147Q38355142-4C827AD2-A773-46CE-8E57-0BB3028116C5Q38578686-B1D9C436-6F49-4DB5-9624-CCDDF66A092AQ38683034-8BE97DB4-2879-4699-B97F-90B32CF52ED4Q38847251-40D46ABA-42AA-4D78-BDC7-97DED4331940Q38864758-E5818961-7443-438B-9B20-D95235FD4B0BQ38989773-8767B30B-8505-4981-9C90-AE8E39A20CA8Q39423479-82745ECC-7E69-4AF4-B365-B70ACD76A360Q42317563-CA6CBAD7-35AD-43F2-A0AE-A6F13B41A949Q48215791-1B98DCB7-1DC9-4273-9508-BECDE0860E4EQ54236409-2E7EFEC5-5B3D-4AAC-A6CB-F42C598E7070Q57138311-9CCF5072-B5E0-4D54-B7E4-983E7DC5EE09
P2860
Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Circulating myeloid-derived su ...... with a risk-adapted strategy.
@en
Circulating myeloid-derived su ...... with a risk-adapted strategy.
@nl
type
label
Circulating myeloid-derived su ...... with a risk-adapted strategy.
@en
Circulating myeloid-derived su ...... with a risk-adapted strategy.
@nl
prefLabel
Circulating myeloid-derived su ...... with a risk-adapted strategy.
@en
Circulating myeloid-derived su ...... with a risk-adapted strategy.
@nl
P2093
P2860
P50
P356
P1476
Circulating myeloid-derived su ...... t with a risk-adapted strategy
@en
P2093
Amalia Figuera
Calogero Vetro
Francesco Di Raimondo
Giovanna Motta
Massimo Ippolito
Nunziatina Laura Parrinello
Ugo Consoli
P2860
P304
P356
10.1111/BJH.13198
P407
P577
2014-11-07T00:00:00Z